A--Notice of Intent to Award Sole Source

The United States Army Medical Research Acquisition Activity (USAMRAA), 820 Chandler Street, Fort Detrick, Maryland, 21702, intends to award a sole source contract to Entegrion Inc. for the continuation of the development of a rapidly acting, platelet derived hemostatic agent (PDHA) for the treatment of non-compressible bleeding through the submission of an Investigational New Drug application with the FDA. Specifically, the Government is seeking the enhancement of Stasix, a PDHA product made from fresh platelets stabilized with paraformaldehyde and subsequently freeze-dried in the presence of albumin which Entegrion holds two licenses and patents/pending patent applications. The proposed contract action is for services for which the Government intends to solicit and negotiate with only one source under the statutory authority permitting other than full and open competition is 10 U.S.C. 2304(c)(1), FAR citation is 6.302-1(a)(2)(iii) and the FAR citation title is only one responsible source and no other supplies or services will satisfy agency requirements for these highly specialized research services. This requirement is in support of the Pharmaceutical Systems Project Management Office (PSPMO) of the U.S. Army Medical Materiel Development Activity (USAMMDA), Fort Detrick, Maryland, 21702. In accordance with FAR Part 6.302-1 (a)(2)(iii), USAMRAA intends to award a sole source contract to Entegrion, Inc., under NAICS code 541711.